Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02325050 · ClinicalTrials.gov registry record · Phase 1
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
NCT02325050 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 164 participants.
The verdict
NCT02325050, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
Interventions
- OTHER Placebo
- BIOLOGICAL MVA-BN-Filo
- BIOLOGICAL Ad26. ZEBOV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2015-01-08 |
| Est. Completion | 2017-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02325050
The ClinicalTrials.gov registry entry for NCT02325050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02325050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02325050 about?
NCT02325050 is a clinical study titled "A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants". The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
What is the current status of trial NCT02325050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2015-01-08. Estimated completion is 2017-05-08.
What interventions are being tested in trial NCT02325050?
The interventions under investigation include: Placebo (OTHER), MVA-BN-Filo (BIOLOGICAL), Ad26. ZEBOV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02325050?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.